Copyright
©The Author(s) 2021.
World J Clin Cases. Aug 16, 2021; 9(23): 6747-6758
Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6747
Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6747
Class of agents | Type | Specific agents | Duration of action |
Antiplatelets | |||
Thienopyridines | Clopidogrel (Plavix), Ticlopidine (Panardine), Prasugrel (Effient), Ticagrelor (Brilinta) | 5-7 d1 | |
Type III PDE inhibitor | Cilostazol (Pretal) | 2 d | |
Acetylsalicylic acid | Aspirin | 7-10 d | |
Other NSAIDs | Ibuprofen (Brufen, Advil), Loxoprofen (Loxonin), Diclofenac (Voltaren) etc. | Varies | |
Anticoagulants | |||
Heparin (unfractionated) | Heparin | 1-2 h | |
Heparin (LMWH) | Dalteparin (Fragmin, iv), Enoxaparin (Clexane, s.c.), Nadroparin (s.c.) | 2-4 h, 6-12 h, 6-12 h | |
Vitamin K antagonist | Warfarin (Coumadin) | 5 d | |
Factor Xa inhibitor (s.c.) | Fondaparinux (Arixtra) | 1-1.5 d | |
DOACs | |||
Direct thrombin inhibitor | Dabigatran (Pradaxa) | 1-2 d | |
Factor Xa inhibitors | Rivaroxaban (Xarelto), Apixaban (Eliquis), Edoxaban (Lixiana) | 1-2 d |
- Citation: Fujikawa T, Naito S. Safety of pancreatic surgery with special reference to antithrombotic therapy: A systematic review of the literature. World J Clin Cases 2021; 9(23): 6747-6758
- URL: https://www.wjgnet.com/2307-8960/full/v9/i23/6747.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i23.6747